Selective Activation of the Adrenomedullin Receptors in Migraine: A Randomized, Double-Blind, Placebo-Controlled Crossover Study
Status: Recruiting
Location: See location...
Intervention Type: Drug, Other
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY
Adrenomedullin is a neuropeptide implicated in the pathogenesis of migraine. This study investigates whether its administration, after pre-treatment with erenumab (a CGRP-receptor blocking monoclonal antibody), can trigger migraine attacks in individuals with migraine without aura.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 65
Healthy Volunteers: f
View:
• Written informed consent has been obtained prior to the initiation of any study-specific procedures.
• Age ≥18 years at the time of screening.
• History of migraine without aura for at least 12 months prior to screening, with a frequency of 1-5 migraine attacks per month, based on medical records and/or patient self-report, and diagnosed in accordance with the ICHD-3 criteria.
Locations
Other Locations
Denmark
Danish Headache Center
RECRUITING
Glostrup Municipality
Contact Information
Primary
Annette Maria Ellekaer Fuchs, PhD Fellow
annette.maria.ellekaer.fuchs@regionh.dk
+4526232421
Backup
Hakan Ashina, Ass. Professor
haakan.ashina@regionh.dk
+4528102495
Time Frame
Start Date: 2026-03-12
Estimated Completion Date: 2032-12-20
Participants
Target number of participants: 26
Treatments
Experimental: Adrenomedullin
Placebo_comparator: Placebo
Sponsors
Leads: Danish Headache Center